{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:25:56Z","timestamp":1787376356988,"version":"build-2736575974"},"reference-count":101,"publisher":"Japan Atherosclerosis Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5551\/jat.rv22059","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T22:11:19Z","timestamp":1787263879000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting Dyslipidemia in Ischemic Stroke: Pathophysiology, Clinical Evidence, and Future Perspectives"],"prefix":"10.5551","author":[{"given":"Junya","family":"Aoki","sequence":"first","affiliation":[{"name":"Department of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke, 2009; 40: 382-388","DOI":"10.1161\/STROKEAHA.108.529537"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke, 2000; 31: 2616-2622","DOI":"10.1161\/01.STR.31.11.2616"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H, Study O. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke, 2003; 34: 863-868","DOI":"10.1161\/01.STR.0000060869.34009.38"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S, Group JS. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res, 2009; 32: 289-298","DOI":"10.1038\/hr.2009.14"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2026; 87: 2624-2757","DOI":"10.1016\/j.jacc.2025.11.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421","DOI":"10.1161\/circ.106.25.3143"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, Group EESD. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J, 2025; 46: 4359-4378","DOI":"10.1016\/j.atherosclerosis.2025.120479"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol, 2002; 22: 1649-1654","DOI":"10.1161\/01.ATV.0000033829.14012.18"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Mathiesen EB, B\u00f8naa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the troms\u00f8 study. Stroke, 2001; 32: 1960-1965","DOI":"10.1161\/hs0901.095639"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Virani SS, Catellier DJ, Pompeii LA, Nambi V, Hoogeveen RC, Wasserman BA, Coresh J, Mosley TH, Otvos JD, Sharrett AR, Boerwinkle E, Ballantyne CM. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis, 2011; 219: 596-602","DOI":"10.1016\/j.atherosclerosis.2011.08.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, Lane T, Neradilek MB, Polissar N, Monick D, Lee C, Underhill H, Yuan C. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging, 2011; 4: 977-986","DOI":"10.1016\/j.jcmg.2011.06.013"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Woo NE, Na HK, Heo JH, Nam HS, Choi JK, Ahn SS, Choi HS, Lee SK, Lee HS, Cha J, Kim YD. Factors for Enhancement of Intracranial Atherosclerosis in High Resolution Vessel Wall MRI in Ischemic Stroke Patients. Front Neurol, 2020; 11: 580","DOI":"10.3389\/fneur.2020.00580"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Suri MF, Qiao Y, Ma X, Guallar E, Zhou J, Zhang Y, Liu L, Chu H, Qureshi AI, Alonso A, Folsom AR, Wasserman BA. Prevalence of Intracranial Atherosclerotic Stenosis Using High-Resolution Magnetic Resonance Angiography in the General Population: The Atherosclerosis Risk in Communities Study. Stroke, 2016; 47: 1187-1193","DOI":"10.1161\/STROKEAHA.115.011292"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zhang P, Zhang Z, Li D, Han R, Li H, Ma J, Xu P, Qi Z, Liu L, Zhang A. Association of remnant cholesterol with intracranial atherosclerosis in community-based population: The ARIC study. J Stroke Cerebrovasc Dis, 2023; 32: 107293","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107293"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, Frankel M, Chimowitz MI, Group WS. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology, 2007; 69: 2063-2068","DOI":"10.1212\/01.wnl.0000279338.18776.26"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ, Investigators ST. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med, 2011; 365: 993-1003","DOI":"10.1056\/NEJMoa1105335"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tomochika Y, Tanaka N, Ono S, Murata K, Muro A, Yamamura T, Tone T, Iwatate M, Ueda K, Morikuni K, Matsuzaki M. Assessment by transesophageal echography of atherosclerosis of the descending thoracic aorta in patients with hypercholesterolemia. Am J Cardiol, 1999; 83: 703-709","DOI":"10.1016\/S0002-9149(98)00974-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Okuzumi A, Ueno Y, Shimada Y, Tanaka Y, Miyamoto N, Yamashiro K, Tanaka R, Hattori N, Urabe T. Impact of low-density lipoprotein to high-density lipoprotein ratio on aortic arch atherosclerosis in unexplained stroke. J Neurol Sci, 2013; 326: 83-88","DOI":"10.1016\/j.jns.2013.01.019"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, Kihara T, Sawada S, Iwamoto N, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol, 2005; 45: 733-742","DOI":"10.1016\/j.jacc.2004.11.039"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kohsaka S, Jin Z, Rundek T, Homma S, Sacco RL, Di Tullio MR. Relationship between serum lipid values and atherosclerotic burden in the proximal thoracic aorta. Int J Stroke, 2010; 5: 257-263","DOI":"10.1111\/j.1747-4949.2010.00437.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Li S, Dong L, Huang Q, Xu J, Xu Z, Mao X, Tang J, Li X, Lin J, Hong D. Dyslipidemia is associated with progressive infarction in anterior circulation single subcortical infarction patients. J Stroke Cerebrovasc Dis, 2023; 32: 107387","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107387"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi I. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci, 2011; 304: 78-82","DOI":"10.1016\/j.jns.2011.02.006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lin J, Dong L, Huang Q, Xiao H, Li S, Tang J, Mao X, Huang P, Li X, Hong D. TG\/HDL-c ratio as a predictor of progressive infarction in patients with anterior circulation single subcortical infarction. Brain Behav, 2024; 14: e3453","DOI":"10.1002\/brb3.3453"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ryu WS, Schellingerhout D, Jeong SW, Nahrendorf M, Kim DE. Association between Serum Lipid Profiles and Early Neurological Deterioration in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis, 2016; 25: 2024-2030","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.009"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nam KW, Kang MK, Jeong HY, Kim TJ, Lee EJ, Bae J, Jeon K, Jung KH, Ko SB, Yoon BW. Triglyceride-glucose index is associated with early neurological deterioration in single subcortical infarction: Early prognosis in single subcortical infarctions. Int J Stroke, 2021; 16: 944-952","DOI":"10.1177\/1747493020984069"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J, Collaboration ERF. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 2010; 375: 132-140","DOI":"10.1016\/S0140-6736(09)61717-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Matsuo R, Ago T, Hata J, Wakisaka Y, Kuroda J, Kuwashiro T, Kitazono T, Kamouchi M, Investigators FSR. Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study. PLoS One, 2016; 11: e0156790","DOI":"10.1371\/journal.pone.0156790"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med, 2024; 391: 2087-2097","DOI":"10.1056\/NEJMoa2405182"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nordestgaard AT, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE, Ridker PM. High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study. The Lancet Neurology, 2025; 24: 920-930","DOI":"10.1016\/S1474-4422(25)00306-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nature reviews Cardiology, 2024; 21: 170-191","DOI":"10.1038\/s41569-023-00937-4"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J, 2017; 38: 2478-2486","DOI":"10.1093\/eurheartj\/ehx163"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Rosenson RS, Brewer HB, Jr., Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature reviews Cardiology, 2016; 13: 48-60","DOI":"10.1038\/nrcardio.2015.124"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Frontiers in endocrinology, 2020; 11: 252","DOI":"10.3389\/fendo.2020.00252"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of lipid research, 2002; 43: 1363-1379","DOI":"10.1194\/jlr.R200004-JLR200"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) KANNEL WB, DAWBER TR, KAGAN A, REVOTSKIE N, STOKES J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med, 1961; 55: 33-50","DOI":"10.7326\/0003-4819-55-1-33"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med, 1971; 74: 1-12","DOI":"10.7326\/0003-4819-74-1-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett, 1976; 72: 323-326","DOI":"10.1016\/0014-5793(76)80996-9"},{"key":"39","unstructured":"39) Connelly D. Statins: the highs and the lows. Pharm J, 2018; 301: 156-157"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 1987; 317: 1237-1245","DOI":"10.1056\/NEJM198711123172001"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307","DOI":"10.1056\/NEJM199511163332001"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J, investigators A. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, investigators C. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Yusuf S, Lonn E, Pais P, Bosch J, L\u00f3pez-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G, Investigators H-. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med, 2016; 374: 2032-2043","DOI":"10.1056\/NEJMoa1600177"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009","DOI":"10.1056\/NEJM199610033351401"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Group L-TIwPiIDS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357","DOI":"10.1056\/NEJM199811053391902"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Risk PsgPSoPitEa. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-1630","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstr\u00f6m B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gr\u00f6nhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, Investigators S. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Group HPSC. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Investigators TtNT. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435","DOI":"10.1056\/NEJMoa050461"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Investigators FSCa. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, L\u00f3pez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation, 2022; 146: 1109-1119","DOI":"10.1161\/CIRCULATIONAHA.122.061620"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, Cho JM, Kang WC, Yoon HJ, Kim WH, Lee JB, Jang JY, Shin S, Park IH, Kwon SU, Kim S, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Kim BK, Investigators E-P. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med, 2026; 394: 1365-1375","DOI":"10.1056\/NEJMoa2600283"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Collaboration CTT. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R, Group SotEoARiC, Collaborative H. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet, 2010; 376: 1658-1669","DOI":"10.1016\/S0140-6736(10)60310-8"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R, Group SC. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med, 2008; 359: 789-799","DOI":"10.1056\/NEJMoa0801936"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Collins R, Armitage J, Parish S, Sleight P, Peto R, Group HPSC. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004; 363: 757-767","DOI":"10.1016\/S0140-6736(04)15690-0"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Investigators SPbARiCL. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006; 355: 549-559","DOI":"10.1056\/NEJMoa061894"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, B\u00e9jot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavall\u00e9e PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touz\u00e9 E, Varenne O, Vicaut \u00c9, Yelles N, Bruckert E, Investigators TStT. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med, 2020; 382: 9","DOI":"10.1056\/NEJMoa1910355"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke, 2012; 43: 2149-2156","DOI":"10.1161\/STROKEAHA.112.655894"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) B\u00e9trisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, Blum MR, Aujesky D, Rodondi N, Gencer B. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc, 2024; 13: e030714","DOI":"10.1161\/JAHA.123.030714"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Monguillon V, Kelly PJ, O\u2019Donoghue ML, Park JG, Bohula EA, Saver JL, Atar D, Keech AC, Sever PS, Wang H, Paiva da Silva Lima G, Sabatine MS, Giugliano RP. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation, 2026; 153: 86-93","DOI":"10.1161\/CIRCULATIONAHA.125.077549"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, Group MS. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163","DOI":"10.1016\/S0140-6736(06)69472-5"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Investigators JElis. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, JELIS Investigators Jp. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke, 2008; 39: 2052-2058","DOI":"10.1161\/STROKEAHA.107.509455"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, Terayama Y, Takagi M, Ibayashi S, Nakamura M, Origasa H, Fukushima M, Mori E, Minematsu K, Uchiyama S, Shinohara Y, Yamaguchi T, Matsumoto M, Collaborators J-S. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine, 2015; 2: 1071-1078","DOI":"10.1016\/j.ebiom.2015.08.006"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R, Investigators E. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018; 41: 1275-1284","DOI":"10.2337\/dc17-2224"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation, 2018; 137: 1997-2009","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Blanco M, Nombela F, Castellanos M, Rodriguez-Y\u00e1\u00f1ez M, Garc\u00eda-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, D\u00e1valos A, Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology, 2007; 69: 904-910","DOI":"10.1212\/01.wnl.0000269789.09277.47"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Mart\u00ednez-S\u00e1nchez P, Rivera-Ord\u00f3\u00f1ez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, D\u00edez-Tejedor E. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol, 2009; 16: 127-133","DOI":"10.1111\/j.1468-1331.2008.02370.x"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM, Investigators SPbARiCL. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2008; 39: 3297-3302","DOI":"10.1161\/STROKEAHA.108.516450"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. Int J Stroke, 2012; 7: 104-111","DOI":"10.1111\/j.1747-4949.2011.00653.x"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Montaner J, Bustamante A, Garc\u00eda-Matas S, Mart\u00ednez-Zabaleta M, Jim\u00e9nez C, de la Torre J, Rubio FR, Segura T, Masju\u00e1n J, C\u00e1novas D, Freijo M, Delgado-Mederos R, Tejada J, Lago A, Bravo Y, Corbeto N, Giralt D, Vives-Pastor B, de Arce A, Moniche F, Delgado P, Rib\u00f3 M, Investigators S. Combination of Thrombolysis and Statins in Acute Stroke Is Safe: Results of the STARS Randomized Trial (Stroke Treatment With Acute Reperfusion and Simvastatin). Stroke, 2016; 47: 2870-2873","DOI":"10.1161\/STROKEAHA.116.014600"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Kim J, Hong U, Yoon CW, Bae JW, Rha JH, Park HK. PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety. Front Neurol, 2024; 15: 1375609","DOI":"10.3389\/fneur.2024.1375609"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Yoshimura S, Uchida K, Daimon T, Takashima R, Kimura K, Morimoto T, Investigator AT. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke, 2017; 48: 3057-3063","DOI":"10.1161\/STROKEAHA.117.017623"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Gao Y, Jiang L, Pan Y, Chen W, Jing J, Wang C, Johnston SC, Amarenco P, Bath PM, Yang Y, Wang T, Han S, Meng X, Lin J, Zhao X, Liu L, Zhao J, Li Y, Zang Y, Zhang S, Yang H, Yang J, Wang Y, Li D, Liu D, Kang G, Investigators I. Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia: The INSPIRES Randomized Clinical Trial. JAMA Neurol, 2024; 81: 741-751","DOI":"10.1001\/jamaneurol.2024.1433"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes\u00e4niemi YA, Sullivan D, Hunt D, Colman P, d\u2019Emden M, Whiting M, Ehnholm C, Laakso M, investigators Fs. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP, Group AS. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, Investigators A-H. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267","DOI":"10.1056\/NEJMoa1107579"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J, Group H-TC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 2014; 371: 203-212","DOI":"10.1056\/NEJMoa1300955"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, Investigators R-I. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22","DOI":"10.1056\/NEJMoa1812792"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J, 2020; 41: 3925-3932","DOI":"10.1093\/eurheartj\/ehaa652"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstr\u00f6m T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020; 324: 2268-2280","DOI":"10.1001\/jama.2020.22258"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JS. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207","DOI":"10.1056\/NEJMoa0807646"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377: 1119-1131","DOI":"10.1056\/NEJMoa1707914"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Investigators OOCa. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP, Investigators O-, ORION-11. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med, 2020; 382: 1507-1519","DOI":"10.1056\/NEJMoa1912387"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging, 2022; 15: 1308-1321","DOI":"10.1016\/j.jcmg.2022.03.002"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS, Investigators V-C. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med, 2026; 394: 117-127","DOI":"10.1056\/NEJMoa2514428"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, P\u00e1ll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM, Investigators P. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ, Investigators CO. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med, 2023; 388: 1353-1364","DOI":"10.1056\/NEJMoa2215024"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Xie S, Galimberti F, Olmastroni E, Luscher TF, Carugo S, Catapano AL, Casula M, Group M-L. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Cardiovasc Res, 2024; 120: 333-344","DOI":"10.1093\/cvr\/cvae034"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, Lincoff AM, Lesogor A, Manning B, Kozlovski P, Cao H, Wang J, Nissen SE. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J, 2025; 287: 1-9","DOI":"10.1016\/j.ahj.2025.03.019"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, Wolski K, Michael L, Haupt A, Krege JH, Investigators AT. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med, 2025; 392: 1673-1683","DOI":"10.1056\/NEJMoa2415818"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, Investigators I. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122","DOI":"10.1056\/NEJMoa0706628"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, Investigators d-O. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099","DOI":"10.1056\/NEJMoa1206797"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE, Investigators A. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med, 2017; 376: 1933-1942","DOI":"10.1056\/NEJMoa1609581"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ, Group HTRC. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med, 2017; 377: 1217-1227","DOI":"10.1056\/NEJMoa1706444"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Endres M. Statins and stroke. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism, 2005; 25: 1093-1110","DOI":"10.1038\/sj.jcbfm.9600116"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_RV22059\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:46:57Z","timestamp":1787374017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_RV22059\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":101,"URL":"https:\/\/doi.org\/10.5551\/jat.rv22059","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"RV22059"}}